Disease · EFO_0003863

urogenital neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. urogenital neoplasm. Diseases, record EFO_0003863. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0003863

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: urogenital neoplasm; Open Targets
Open Targets ID: EFO_0003863; Open Targets
Other names: Cancer, Genito-urinary, Cancer, Genitourinary, Cancer, Urogenital, Cancers, Genito-urinary, Cancers, Genitourinary, Cancers, Urogenital, GENITO URINARY NEOPL, GENITOURINARY NEOPL, Genito urinary Cancer, Genito-urinary Cancers, Genito-urinary Neoplasm, Genito-urinary Neoplasms, Genitourinary Cancer, Genitourinary Cancers, Genitourinary Neoplasm, Genitourinary Neoplasms, NEOPL GENITOURINARY, NEOPL UROGENITAL, Neoplasm, Genito-urinary, Neoplasm, Genitourinary, Neoplasm, Urogenital, Neoplasms, Genito-urinary, Neoplasms, Genitourinary, Neoplasms, Urogenital, UROGENITAL NEOPL, Urogenital Cancer, Urogenital Cancers, Urogenital Neoplasms; Open Targets
MeSH: D014565; MeSH
Highest stage of its drugs: Phase 3, for 13 of its 40 drugs, from ClinicalTrials.gov; Open Targets

Drugs40

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ENFORTUMAB VEDOTIN	CHEMBL3301589	Antibody drug conjugate	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
AVELUMAB	CHEMBL3833373	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 40

See all 40 drugs

Targets105

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TUBA1A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7280	Drugs and targets
TUBB2B	Tubulin	5	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/347733	Drugs and targets

1 to 10 of 105

See all 105 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer	Phase 3	1,314	2025-09-18	Urothelial Cancer	CISPLATIN, GEMCITABINE, IPILIMUMAB, NIVOLUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02516241	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	Phase 3	1,126	2021-05-13	Urothelial Cancer	DURVALUMAB, TREMELIMUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT04223856	Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer	Phase 3	886	2024-09-27	Urothelial Cancer	ENFORTUMAB VEDOTIN, PEMBROLIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02603432	A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)	Phase 3	700	2020-12-17	Urothelial Cancer	AVELUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03390504	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations	Phase 3	629	2025-05-14	Urothelial Cancer	ERDAFITINIB, PEMBROLIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03474107	A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	Phase 3	608	2021-08-24	Ureteral Cancer, Urothelial Cancer, Bladder Cancer	DOCETAXEL, ENFORTUMAB VEDOTIN, PACLITAXEL, VINFLUNINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02256436	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)	Phase 3	542	2017-08-31	Urothelial Cancer	DOCETAXEL, PACLITAXEL, PEMBROLIZUMAB, VINFLUNINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02335424	Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)	Phase 2	374	2019-07-05	Urothelial Cancer	PEMBROLIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02033993	Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.	Phase 2	199	2020-01-18	Urothelial Cancer	PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05259696	Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)	Phase 1/2	69	2025-08-20	Oncology, Melanoma, Ovarian Cancer, NSCLC, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Cancer, CRC, Colon Cancer, Breast Cancer, Gastric Cancer, EGJ, Esophagogastric Junction Cancer, Head and Neck Cancer, Urothelial Cancer, Bladder Cancer	CEMIPLIMAB	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Enfortumab Vedotin + Pembrolizumab vs Standard of Care: deaths from any cause	133 of 442	226 of 444	886	NCT04223856	Trial comparisons
Enfortumab Vedotin + Pembrolizumab vs Standard of Care: serious adverse events	220 of 440	169 of 433	873	NCT04223856	Trial comparisons
Avelumab + Best Supportive Care (BSC) vs Best Supportive Care: deaths from any cause	225 of 344	242 of 345	689	NCT02603432	Trial comparisons
Avelumab + Best Supportive Care (BSC) vs Best Supportive Care: serious adverse events	111 of 344	73 of 345	689	NCT02603432	Trial comparisons
Avelumab + Best Supportive Care (BSC) vs Best Supportive Care: Number of Participants With Cluster of Differentiation 8 (CD8) T Lymphocytes (Cytotoxic T Lymphocytes)	148 of 337	134 of 326	663	NCT02603432	Trial comparisons
Enfortumab Vedotin 1.25 mg/kg vs Chemotherapy: Number of Participants With Treatment Emergent Adverse Events	290 of 296	288 of 291	587	NCT03474107	Trial comparisons
Enfortumab Vedotin vs Chemotherapy: deaths from any cause	130 of 296	161 of 291	587	NCT03474107	Trial comparisons
Enfortumab Vedotin vs Chemotherapy: serious adverse events	138 of 296	128 of 291	587	NCT03474107	Trial comparisons
Pembrolizumab vs Control: Number of Participants Who Experienced an Adverse Event (AE)	250 of 266	250 of 255	521	NCT02256436	Trial comparisons
Pembrolizumab vs Control: Number of Participants Who Discontinued Study Treatment Due to an AE	28 of 266	36 of 255	521	NCT02256436	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials53

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32940628	RESULT	1	PubMed
32552471	RESULT	1	PubMed
28967485	RESULT	1	PubMed
24318901	RESULT	1	PubMed
43004726	DERIVED	1	PubMed
43001410	DERIVED	1	PubMed
41925239	DERIVED	1	PubMed
41563650	DERIVED	1	PubMed
41039930	DERIVED	1	PubMed
41015742	DERIVED	1	PubMed

1 to 10 of 53

See all 53 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0003863

GET https://conductscience.org/api/diseases/v1/EFO_0003863/drugs?page=2

API reference For AI assistants